VAXXAS’ new needle-free
vaccine delivery system,
Nanopatch, has been awarded the
Best Venture Capital Investment at
the 2012 Vaccine Industry
Excellence Awards.
The Nanopatch was created by
Prof Mark Kendall and his team at
University of Queensland’s
Australian Institute for
Bioengineering and Nanotechnology,
and was made commercially viable
by a $15m investment in Vaxxas Pty
Ltd by OneVentures, Brandon
Capital Partners, the Medical
Research Commercialisation Fund,
and US-based HealthCare Ventures.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 12 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 12
THE Senate’s Community Affairs Legislation Committee is holding a two-day inquiry into the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Bill 2024, which is currently under discussion in Federal Parliament.
A NEW study from the University of South Australia has discovered that an increased cardio-fitness level will reduce risk of death from any cause by nearly 20%.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.